For the fourth quarter of 2015 ending Dec. 31, Madison-based Exact Sciences reported a net loss of $40 million (41 cents/share) on revenues of $14.4 million. That compares to a net loss of $32.4 million (38 cents/share) on revenues of $1.5 million for the same period in 2014.
For all of 2015, Exact Sciences reported a net loss of $157.8 million ($1.71/share) on revenues of $39.4 million, compared to a net loss of $100 million ($1.25/share) on revenues of $1.8 million for all of 2014.
The company, which developed Cologuard, a stool-based test for colon cancer, completed 38,000 tests in the fourth quarter, and more than 104,000 tests for the entire year.
